 The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Incs NASDAQ: INO global Phase 3 segment of its INNOVATE Phase 23 trial for INO-4800, DNA COVID-19 vaccine candidate. Related Content: Inovios DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study. 